Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Thomas F. Unger"'
Autor:
Murray Lumpkin, Mark R. Trusheim, Gigi Hirsch, Richard Bergstrom, Pamela Gavin, Nathalie Seigneuret, Anton Hoos, Magda Chlebus, Michel Goldman, Karin Van Baelen, Duane Schulthess, Lynn G. Baird, Sarah Garner, Thomas F. Unger
Publikováno v:
Therapeutic innovationregulatory science. 50(3)
After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated
Publikováno v:
Expert Opinion on Orphan Drugs. 2:1147-1150
The Orphan Drug Act of 1983 in the United States collapsed the barrier between patients with rare diseases and promising drug treatments. Over the subsequent 30 years, > 400 ‘orphan drugs’ became available to them. However, with thousands of rare
Autor:
Lynn G. Baird, E. V. Sigal, Jeffrey S. Brown, D. Tan, Robyn Lim, H. G. Eichler, Kenneth A. Oye, Vicki L. Seyfert-Margolis, E Pezalla, J Ferguson, Brian O'Rourke, Sarah Garner, J. Sobotka, John C W Lim, Chester L. Drum, Thomas F. Unger, P. Honig, Diane Shoda, Mathias Hukkelhoven, G. Neil, E. Abadie, M. M. Lumpkin, Gigi Hirsch
Publikováno v:
Clinical Pharmacology & Therapeutics. 91:426-437
Traditional drug licensing approaches are based on binary decisions. At the moment of licensing, an experimental therapy is presumptively transformed into a fully vetted, safe, efficacious therapy. By contrast, adaptive licensing (AL) approaches are
Autor:
Sarah Garner, J Raine, J Maraganore, Y Le Cam, Lynn G. Baird, Brigitte Bloechl-Daum, M Skinner, Tatsuya Kondo, P Huckle, Trusheim, Wim G. Goettsch, Hubert G. M. Leufkens, Anton Hoos, H G Eichler, D. Samaha, J Ferguson, E Pezalla, JR Teagarden, Gigi Hirsch, R Barker, Toshiyoshi Tominaga, R Chua, Thomas F. Unger, Carole Longson, Kenneth A. Oye, Guido Rasi, Jeffrey S. Brown, Spiros Vamvakas, S Del Signore, S. Tunis, PD Siviero, U Dugan, Peter Honig, Tomas Salmonson, Robyn Lim, J Haigh, Murray Lumpkin, F Børlum‐Kristensen, Brian O'Rourke, Sebastian Schneeweiss, Francesco Pignatti
Publikováno v:
Clinical Pharmacology and Therapeutics
The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the envi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31af74ff579e5ce5f1309473c8d62887
http://hdl.handle.net/2108/247946
http://hdl.handle.net/2108/247946
Publikováno v:
Biochemical and Biophysical Research Communications. 299:659-662
The phthalate ester insensitive blue-green algae (Synechococcus lividus) were used as a food source to extend the survival of synchronously hatched brine shrimp (Artemia salina) larvae allowing measurement of a reduced toxic response to phthalate est
Publikováno v:
SPIE Proceedings.
A novel identification technique called antibody profiling was examined as an alternative to DNA-based methods for matching crime scene evidence to a suspect. This technique provides results within 2 hours, is 1/100 the cost of DNA tests, and does no
Publikováno v:
Proceedings. Biological sciences. 246(1316)
We investigated the existence of an endogenous uptake system for folate in Xenopus laevis oocytes. This was done by performing uptake measurements using [ 3 H]folic acid. Uptake of folic acid was linear with time for 4 h of incubation, and was simila
Publikováno v:
Bulletin of environmental contamination and toxicology. 39(1)
The authors' continuing efforts to characterize the molecular basis for the development-stage-dependent phthalate ester toxicity in the brine shrimp, Artemia, led them to consider a number of microorganisms as foraging species for Artemia. The sensit
Conference
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.